News Releases

Mar 04, 2026 Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Mar 04, 2026 Pulmonx Announces Closing of up to $60 Million Credit Facility
Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung
Feb 20, 2026 Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading
Print Page
Email Alerts
Contact IR
RSS Feeds